Therefore, HOXA13 is a potential prognostic biomarker, and targeting the IGF1-HOXA13-IGF1R oncogenic loop may provide a potential therapeutic strategy to inhibit HOXA13-driven CRC metastasis. Here, IGF1 is linked to colorectal carcinoma.